| Today's Big NewsNov 10, 2022 |
|
Talent matters more than ever. And Greater Philadelphia’s growth and development of this critical asset is one reason JLL ranked the region as its No. 5 Life Sciences cluster in the U.S. Learn how the region can fuel your company’s growth. Learn more. 
|
|
| By Kevin Dunleavy Seven months after Seagen was rocked by the domestic abuse arrest of founder, chairman and CEO Clay Siegall and his subsequent resignation, the powerhouse Seattle biotech has found its new leader, appointing oncology veteran David Epstein as its CEO. Epstein, 59, spent more than 25 years at Novartis, building its oncology business from “initiation to the second largest in the world,” Seagen said in a release. |
|
|
|
By Dave Muoio ACEP, AMA and 31 other provider groups warned that waiting room deaths are becoming more common as hospital emergency departments have reached a "breaking point." The groups called on the Biden administration to call a summit of industrywide stakeholders “to identify immediate and long-term solutions to this urgent problem.” |
By Nick Paul Taylor AstraZeneca has tossed out two early-phase drug development programs in its quarterly review, adding a Moderna-partnered solid tumor candidate and in-house chronic kidney disease treatment to its discard pile. |
By Fraiser Kansteiner Biogen’s board has tapped former Sanofi chief Christopher Viehbacher to assume the CEO throne on November 14. Viehbacher will also take over the role of director from Vounatsos, who plans to stick around at the struggling biotech for a “limited period of time” to smooth the CEO switch, Biogen said in a securities filing. |
|
Wednesday, November 16, 2022 | 11am ET / 8am PT Process characterization is an important step in the product development journey. Join this webinar where experts share case studies in developing a stepwise approach for process validation. Register now. 
|
|
By Andrea Park In the wake of a 2021 that saw BD chart a whopping 18% increase in its year-over-year revenue, the medtech giant was unable to recreate that success. |
By Gabrielle Masson Tiziana Life Sciences is following biotech’s third-quarter cull trend, though it’s attempting to do so more covertly by putting several of its pipeline programs on the shelf in a “near-term focus” strategic update. |
By Kevin Dunleavy Novartis is shuttering a gene therapy manufacturing facility near Chicago. Closure of the site in Libertyville, Illinois, will force 275 employees out of their jobs. The site produces blockbuster spinal muscular atrophy treatment Zolgensma. In other layoff news, Sumitomo will lay off 360 from its site in Marlborough, Massachusetts, while Valneva said Thursday that it will reduce its workforce by 20% to 25%. |
By Conor Hale Rebranded as the Pilot test, the new name carries added meaning: it’s Roche’s first over-the-counter diagnostic to enter the U.S. market. |
By Paige Minemyer Oscar Health is aiming to reach profitability by 2024 and to achieve that goal is focusing on the area where it's seen the most success to date: the individual market, executives said late Tuesday. |
By Fraiser Kansteiner The European Commission signed off on Sanofi and GSK's booster shot to augment protection against COVID-19 in adults ages 18 and up, making VidPrevtyn Beta the first next-gen, protein-based adjuvanted coronavirus vaccine approved in Europe. |
By Annalee Armstrong The FDA was pretty clear a year and a half ago that BrainStorm Cell Therapeutics’ amyotrophic lateral sclerosis therapy was not ready for prime time—but perhaps this latest rejection will really send the message home. |
By Andrea Park At the core of the plan is a goal to narrow the company’s product portfolio, by redirecting focus toward new products launched in the last year. |
By Robert King A new report finds an increase in Medicare Advantage spending on alternative payment models that feature two-sided financial risk. |
By Nick Paul Taylor Veru has lost a split decision at its FDA advisory committee, with the experts voting eight to five against the known and potential benefit-risk profile of VERU-111 in hospitalized moderate to severe COVID-19 patients who are at high risk for acute respiratory distress syndrome. |
Fierce podcasts Don't miss an episode |
| This week on "Podnosis," we talk about charity care policies and how they've changed since the start of the COVID-19 pandemic. We also talk about the 10 Fierce Healthcare's Women of Influence honorees and how they are making a big impact on healthcare. |
|
|---|
|
|
|
Tuesday, November 15, 2022 | 1pm ET / 10am PT In this webinar, learn how Medable is focused on improving access to clinical trials for patients, supporting the innovation of clinical trial delivery and offering greater choices for participation and engagement to patients. Register now. 
|
|
Webinar Twist Bioscience CSO Dr. Aaron Sato shares how Twist's tools for antibody discovery have been applied to identify antibodies against diverse and challenging targets. See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions. Presented by: Twist Bioscience |
Whitepaper This paper outlines how gene therapy supply chains are different from traditional biopharma products, as well as the factors that are essential to success. Sponsored by: Blue Matter |
Video Revolutionize your monoclonal antibody (mAb) manufacturing process with the Gibco™️ Efficient-Pro™️ Medium and Feed System. Watch our how-to video. Sponsored by: Thermo Fisher Scientific |
Whitepaper What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent |
Research Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent |
Whitepaper How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
Whitepaper Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
Webinar Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics |
Whitepaper Clarus Therapeutics (Clarus) is a men’s specialty pharmaceutical company that partnered with Catalent to develop a unique and convenient drug delivery form for their hormone replacement therapy. Sponsored by: Catalent |
Whitepaper Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success. Sponsored by: Catalent |
eBook Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored By: Catalent |
Whitepaper Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored By: Catalent |
Whitepaper What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored By: Catalent |
| |
|
